MCID: TNN002
MIFTS: 35

Tinea Unguium

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Tinea Unguium

MalaCards integrated aliases for Tinea Unguium:

Name: Tinea Unguium 12 15 71 32
Cellulitis and Abscess of Upper Arm and Forearm 12
Cellulitis and Abscess of Finger and Toe 12
Cellulitis and Abscess of Gluteal Region 12
Cellulitis and Abscess of Buttock 12
Onychomycosis Due to Dermatophyte 12
Cellulitis and Abscess of Finger 12
Cellulitis and Abscess of Trunk 12
Cellulitis and Abscess of Face 12
Dermatophytic Onychomycosis 12
Dermatophytosis of Nail 12
Cellulitis and Abscess 12
Dermatophytic Onychia 12
Onychomycosis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13074
ICD9CM 34 681.9
ICD10 32 B35.1
UMLS 71 C0007644 C0040261 C4048550

Summaries for Tinea Unguium

Disease Ontology : 12 A dermatophytosis that results in fungal infection located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which cause separation of the nail plate from the nail bed and has symptom thickening of subungueal area. Sometimes, white islands are seen on the external nail plates. These gradually coalesce until the entire nail plate is involved.

MalaCards based summary : Tinea Unguium, also known as cellulitis and abscess of upper arm and forearm, is related to dermatophytosis and dermatomycosis, and has symptoms including thickening of subungueal area An important gene associated with Tinea Unguium is STAT1 (Signal Transducer And Activator Of Transcription 1). The drugs Tazarotene and Ciclopirox have been mentioned in the context of this disorder. Affiliated tissues include nail, testes and skin.

Wikipedia : 74 Onychomycosis, also known as tinea unguium, is a fungal infection of the nail. Symptoms may include... more...

Related Diseases for Tinea Unguium

Diseases related to Tinea Unguium via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
# Related Disease Score Top Affiliating Genes
1 dermatophytosis 31.4 SQLE FLNA CBSL B4GALNT2
2 dermatomycosis 31.1 CBSL B4GALNT2
3 tinea capitis 30.8 SQLE CBSL B4GALNT2
4 tinea pedis 30.7 SQLE MSRA CBSL B4GALNT2
5 fungal infectious disease 30.3 STAT1 CRP CBSL B4GALNT2
6 tinea corporis 30.0 SQLE FLNA CBSL B4GALNT2
7 uvulitis 10.5
8 cellulitis 10.4
9 emphysematous cholecystitis 10.3 GPT CRP
10 ascending cholangitis 10.3 GPT CRP
11 ankylosing spondylitis 1 10.3 GPT CRP
12 splenic abscess 10.3 GPT CRP
13 critical illness polyneuropathy 10.3 GPT CRP
14 acalculous cholecystitis 10.3 GPT CRP
15 white piedra 10.3 CBSL B4GALNT2
16 tinea manuum 10.3 CBSL B4GALNT2
17 otomycosis 10.3 CBSL B4GALNT2
18 granulomatous hepatitis 10.3 GPT CRP
19 viral laryngitis 10.3 GPT CRP
20 trichosporonosis 10.3 CBSL B4GALNT2
21 acute cholangitis 10.3 GPT CRP
22 cholecystolithiasis 10.3 GPT CRP
23 eumycotic mycetoma 10.3 CBSL B4GALNT2
24 heart aneurysm 10.3 GPT CRP
25 coronary aneurysm 10.3 GPT CRP
26 splenic infarction 10.3 GPT CRP
27 phaeohyphomycosis 10.3 CBSL B4GALNT2
28 abdominal tuberculosis 10.3 GPT CRP
29 paralytic ileus 10.3 GPT CRP
30 48,xyyy 10.3
31 hydrops of gallbladder 10.3 GPT CRP
32 common bile duct disease 10.3 GPT CRP
33 pyuria 10.3 GPT CRP
34 pityriasis versicolor 10.3 SQLE CBSL
35 subcutaneous mycosis 10.3 CBSL B4GALNT2
36 kwashiorkor 10.3 GPT CRP
37 analbuminemia 10.3 GPT CRP
38 volvulus of midgut 10.3 GPT CRP
39 hypopyon 10.3 CRP B4GALNT2
40 superficial mycosis 10.3 CBSL B4GALNT2
41 leprosy 3 10.3
42 erythema multiforme 10.3
43 allergic hypersensitivity disease 10.3
44 paronychia 10.3
45 urticaria 10.3
46 keratosis 10.3
47 neuritis 10.3
48 human immunodeficiency virus infectious disease 10.3
49 bullous pemphigoid 10.3
50 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.3

Graphical network of the top 20 diseases related to Tinea Unguium:



Diseases related to Tinea Unguium

Symptoms & Phenotypes for Tinea Unguium

Symptoms:

12
  • thickening of subungueal area

Drugs & Therapeutics for Tinea Unguium

Drugs for Tinea Unguium (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
3
Amorolfine Approved, Investigational Phase 4 78613-35-1
4
carbamide peroxide Approved Phase 4 124-43-6
5
Tavaborole Approved, Investigational Phase 4 174671-46-6
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Bifonazole Approved, Investigational Phase 4 60628-96-8 2378
8
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
9
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
10
Efinaconazole Approved Phase 4 164650-44-6
11 Dermatologic Agents Phase 4
12 Keratolytic Agents Phase 4
13 Pharmaceutical Solutions Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Hormone Antagonists Phase 4
16 Hormones Phase 4
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18
Hydroxyitraconazole Phase 4
19 Anti-Bacterial Agents Phase 4
20 Antiprotozoal Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Amebicides Phase 4
23 Antioxidants Phase 4
24 Protective Agents Phase 4
25 Liposomal amphotericin B Phase 4
26
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
27
Luliconazole Approved Phase 2, Phase 3 187164-19-8
28
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
29
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
30
Econazole Approved Phase 2 27220-47-9 3198
31
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
32
Naftifine Approved Phase 2 65472-88-0 47641 73342
33
Aminolevulinic acid Approved Phase 2 106-60-5 137
34
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
35
Diclofenac Approved, Vet_approved Phase 2 15307-86-5 3033
36
Ethanol Approved Phase 2 64-17-5 702
37
Polihexanide Approved, Investigational Phase 2 28757-47-3
38 Albaconazole Investigational Phase 2 187949-02-6
39 Antifungal Agents Phase 2
40 Immunosuppressive Agents Phase 2
41 Immunologic Factors Phase 2
42 Benzonidazole Phase 2
43 Anti-Infective Agents, Local Phase 2
44 Analgesics, Non-Narcotic Phase 2
45 Analgesics Phase 2
46 Cyclooxygenase Inhibitors Phase 2
47 Anti-Inflammatory Agents Phase 2
48 Antirheumatic Agents Phase 2
49 Anti-Inflammatory Agents, Non-Steroidal Phase 2
50 Anti-Infective Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 127)
# Name Status NCT ID Phase Drugs
1 A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
4 A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
5 A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails Completed NCT02812771 Phase 4 Efinaconazole
6 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
7 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
8 Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
9 Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
10 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
11 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
12 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
13 Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
14 An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
15 Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
16 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
17 A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Active, not recruiting NCT03280927 Phase 4 Jublia®
18 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Unknown status NCT03171584 Phase 3 Terbinafine
19 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
20 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
21 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
22 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
23 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
24 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
25 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
26 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
27 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
28 Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis Completed NCT02547701 Phase 3 P-3058
29 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
30 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
31 Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
32 A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
33 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Completed NCT03168841 Phase 3 Efinaconazole Topical
34 A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
35 Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis) Completed NCT00935649 Phase 2, Phase 3
36 A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
37 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
38 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
39 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks Terminated NCT01208129 Phase 3 NAB001;Placebo control
40 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
41 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
42 Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study Unknown status NCT00771732 Phase 2
43 A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail Unknown status NCT00385502 Phase 2 EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
44 AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE Unknown status NCT01528813 Phase 2 Amorolfine lacquer
45 Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
46 A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis Unknown status NCT03471455 Phase 2 Isotretinoin;Terbinafine;Itraconazole 200 mg
47 Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium. Completed NCT00253305 Phase 2 Organogel of naftifine, 2%;Organogel of terbinafine, 2%;Organogel of naftifine, 6%;Organogel of terbinafine, 6%
48 An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail Completed NCT01484145 Phase 2 Terbinafine HCl
49 An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis Completed NCT00680160 Phase 2 AN2690
50 A Subject Blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail Completed NCT01080079 Phase 2 Terbinafine Hydrochloride

Search NIH Clinical Center for Tinea Unguium

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ciclopirox
Ciclopirox olamine
Itraconazole
tavaborole
terbinafine
Terbinafine hydrochloride

Genetic Tests for Tinea Unguium

Anatomical Context for Tinea Unguium

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Unguium:

19
Nail

MalaCards organs/tissues related to Tinea Unguium:

40
Testes, Skin

Publications for Tinea Unguium

Articles related to Tinea Unguium:

(show top 50) (show all 276)
# Title Authors PMID Year
1
Epidemiological survey of 42 403 dermatophytosis cases examined at Nagasaki University Hospital from 1966 to 2015. 61
32293052 2020
2
Whole-genome resequencing of Trichophyton rubrum provides insights into population differentiation and drug resistance. 61
31538279 2020
3
Skin Infections and Outpatient Burn Management: Fungal and Viral Skin Infections. 61
31995350 2020
4
Molecular identification of isolates of the Trichophyton mentagrophytes complex. 61
31929737 2020
5
Epidemiology of dermatophytic infections between 2008 and 2017 in Barcelona, Spain. 61
31076176 2019
6
Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole. 61
31353607 2019
7
In search of the source of dermatophytosis: Epidemiological analysis of Trichophyton verrucosum infection in llamas and the breeder (case report). 61
31538413 2019
8
Internal environment of footwear is a risk factor for tinea pedis. 61
31436337 2019
9
Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. 61
31321333 2019
10
Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. 61
30768808 2019
11
Differences Between Patient-Reported Versus Clinician-Observed Nonulcerative Signs and Symptoms of the Foot in Patients With Diabetes Mellitus. 61
30747799 2019
12
Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis. 61
31474693 2019
13
Detection of Trichophyton rubrum and Trichophyton interdigitale in onychomycosis using monoclonal antibodies against Sub6 (Tri r 2). 61
30152879 2019
14
2016 Epidemiological Survey of Dermatomycoses in Japan. 61
31474694 2019
15
Epidemiological and clinical aspects of dermatophytoses in Eastern Slovakia: a retrospective three-year study. 61
30817878 2018
16
Ultrastructural changes of Trichophyton rubrum in tinea unguium after itraconazole therapy in vivo observed using scanning electron microscopy. 61
30387190 2018
17
Molecular Epidemiological Analysis of the Spreading Conditions of Trichophyton in Long-Term Care Facilities in Japan. 61
30175735 2018
18
Topical efinaconazole: A promising therapeutic medication for tinea unguium. 61
30035311 2018
19
Tinea unguium onychomycosis caused by dermatophytes: a ten-year (2005-2014) retrospective study in a tertiary hospital in Singapore. 61
29552686 2018
20
Epidemiology of dermatophytoses in 31 municipalities of the province of Buenos Aires, Argentina: A 6-year study. 61
29606407 2018
21
Characterizing the clinical isolates of dermatophytes in Hamadan city, Central west of Iran, using PCR-RLFP method. 61
29439839 2018
22
Subungual Amelanotic Melanoma Masquerading as Onychomycosis. 61
29755903 2018
23
Common Child and Adolescent Cutaneous Infestations and Fungal Infections. 61
29198783 2018
24
Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". 61
29849837 2018
25
Response to: Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". 61
29951161 2018
26
Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. 61
29323069 2017
27
High prevalence of superficial white onychomycosis by Trichophyton interdigitale in a Japanese nursing home with a geriatric hospital. 61
28436564 2017
28
Epidemiology of dermatomycoses in Kerman province, southeast of Iran: A 10-years retrospective study (2004-2014). 61
28757272 2017
29
Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium. 61
28281037 2017
30
Examining the accuracy of visual diagnosis of tinea pedis and tinea unguium in aged care facilities. 61
28379097 2017
31
Epidemiological status of dermatophytosis in Guilan, north of Iran. 61
29302626 2017
32
New Antifungal Agents and New Formulations Against Dermatophytes. 61
27502503 2017
33
Tinea Unguium: Diagnosis and Treatment in Practice. 61
27787643 2017
34
Dermatophyte Antigen Kit. 61
28566667 2017
35
[Affinity of Luliconazole for Human Nail Derived Keratin]. 61
29187718 2017
36
Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia. 61
28852411 2017
37
Characterization of clinically important dermatophytes in North of Iran using PCR-RFLP on ITS region. 61
27496524 2016
38
Is the Dermatophyte Test Strip truly useful for the diagnosis of tinea unguium? Inquiry into "Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes". 61
27910169 2016
39
[Causative agents of superficial mycoses isolated in Dakar, Senegal: Retrospective study from 2011 to 2015]. 61
27592054 2016
40
[Tinea unguium with Microsporum langeronii and Trichophyton soudanense revealing tinea capitis with M. langeronii]. 61
27592053 2016
41
Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes. 61
26992478 2016
42
Production of an anti-dermatophyte monoclonal antibody and its application: immunochromatographic detection of dermatophytes. 61
27250927 2016
43
Identification of three yeast species using the conventional and internal transcribed spacer region sequencing methods as first or second global record from human superficial infections. 61
27392537 2016
44
Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. 61
27659511 2016
45
Epidemiological Aspects of Dermatophytosis in Khuzestan, southwestern Iran, an Update. 61
26886443 2016
46
Epidemiology of Superficial Fungal Infections in Guangdong, Southern China: A Retrospective Study from 2004 to 2014. 61
26883512 2016
47
[Superficial mycoses: casuistry of the Mycology Department of the Instituto Nacional de Higiene "Rafael Rangel", Caracas, Venezuela (2001-2014)]. 61
27382801 2016
48
Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran. 61
26369643 2016
49
Development and Evaluation of a Novel Real-Time PCR for Pan-Dermatophyte Detection in Nail Specimens. 61
26412381 2016
50
[Affinity of Luliconazole to Keratin Prepared from Healthy Human Nailand Porcine Hoof]. 61
26936352 2016

Variations for Tinea Unguium

ClinVar genetic disease variations for Tinea Unguium:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1):c.821G>A (p.Arg274Gln)SNV Pathogenic 30085 rs387906760 2:191859910-191859910 2:190995184-190995184

Expression for Tinea Unguium

Search GEO for disease gene expression data for Tinea Unguium.

Pathways for Tinea Unguium

GO Terms for Tinea Unguium

Sources for Tinea Unguium

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....